|
100%
agree
35 votes
|
New Medicare reform has led to the coverage Humira |
|
100%
agree
5 votes
|
Abbott is awaiting FDA approval for additional indications of Humira |
|
100%
agree
5 votes
|
Xience V drug-eluting stent has had successful late-stage clinical trials |
|
10%
agree
10 votes
|
Medicare could negatively affect Abbott's pricing in the long run |
|
16%
agree
12 votes
|
Abbott's R&D expenditures are much less than their competition |
|
18%
agree
16 votes
|
Pipeline questions |
June 19, 2013
Abbott Laboratories (NYSE: ABT) is the largest company in the nutritional products market and the second largest company in the worldwide market for diagnostic products. The company manufactures a number of nutritional and pharmaceutical products, laboratory diagnostics, pharmaceutical therapies and medical devices, including the arthritis medication Humira and the coronary stent Xience. In FY 2010, Abbott generated revenues of $35.17B and net earnings of $4.6B.[1]
Abbott and the rest of the pharmaceutical industry are continually under pressure from expiring patents. Patent expiration allows generic drug companies to lower prices for a certain medication by producing their own versions, increasing competition for that product's market.
(Read more at Wikinvest
) - Corporate Overview
- Recent Acquisitions
- Business Segments
- Pharmaceutical Products ($19.9 billion, 56.6% of 2010 revenues)[6]
- Nutritional Products ($5.5 billion, 15.7% of 2010 revenues)[8]
- Diagnostics ($3.8 billion, 10.8% of 2010 revenues)[9]
- Vascular ($3.2 billion, 9.1% of 2010 revenues)[10]
- Research and Development ($3.7B, 10.5% of 2010 revenues)[12]
- Trends and Forces
- Government regulation challenge
- Tightening FDA Regulations
- Expiring patents threat
- Strong pipeline; diverse businesses
- Generic pharmaceuticals: direct competition
- Medicare coverage patterns
- Effect of US politics
- Competition
- References
